Neuros Medical raises $42M Series D ahead of ALTIUS pivotal trial readout
Summary
Cleveland-based Neuros Medical secured $42M Series D led by Deerfield Management, with Endeavour Vision and new investor Foresite Capital, as the ALTIUS pivotal trial for residual limb pain in amputees nears primary endpoint completion. The round is structured to fund pre-commercialization activities contingent on positive trial results expected in Q2 2025.
Why it matters
Pre-commercialization funding contingent on trial results is the right capital strategy when pivotal data is imminent. Deerfield leading a $42M round with commercial-stage timing indicates they have reviewed the ALTIUS interim data through their investment diligence process and see a positive primary endpoint as highly probable.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial